Loading
Life sciences · Journal article
Memo - Magazine of European Medical Oncology · October 23, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Summary Current treatment options for advanced kidney cancer rely on small molecules targeting tyrosine kinase inhibitors (TKI), hypoxia-inducible factor 2 alpha (HIF2α), and mammalian target of rapamycin (mTOR) as well as antibodies directed against immune checkpoint inhibitors (ICI). Programmed cell death protein 1 (PD-1) antagonists, in particular, represent the cornerstone of modern therapies for early-stage and advanced disease. The 2026 ASCO annual meeting focused on immuno-oncology (IO) and delivered praxis-defining data for both clear cell (cc) and non-clear cell (ncc) renal cell carcinoma (RCC). The RAMPART trial evaluated adjuvant durvalumab in high-risk RCC patients, whereas the exploratory analysis of the KEYNOTE-564 trial defined the role of circulating tumor (ct) DNA as a biomarker of disease recurrence after nephrectomy. In the metastatic setting, two clinical trials confirmed the efficacy of treatment regimens combining ICIs and TKIs for nccRCC. Overall, these studies confirm the key role of IO in RCC across the entire disease spectrum.